

August 15, 2018

Press Release

Nobelpharma Co., Ltd.

### **Lunabell® Compound Tablets LD and ULD Authorized Generic**

Today, ASKA Pharmaceutical Company, Ltd. (“ASKA”, Head Office: Minato-ku, Tokyo, President: Takashi Yamaguchi) announced that they have obtained marketing approval for the dysmenorrhea drug FREWELL® Compound Tablets LD (ASKA) and FREWELL® Compound Tablets ULD (ASKA).

Lunabell® Compound Tablets LD and Lunabell® Compound Tablets ULD, developed by Nobelpharma Co., Ltd. (“Nobelpharma”, Head Office: Chuo-ku, Tokyo, President and CEO: Jin Shiomura) were forerunner products for both products, and the products which are authorized generic (AG) drugs use equivalent Active Pharmaceutical Ingredient (API), additives, and manufacturing methods. These are the first AG in Japan for low dose and ultra-low dose estrogen/progestin tablets, and also the first AG for Nobelpharma’s products.

ASKA plans to conduct exclusive sales of the products based on the sales licensing agreement with Nobelpharma.

“FREWELL® Compound Tablets” is the uniform brand name for generic drug products of Lunabell® Compound Tablets (norethisterone/ethinylestradiol tablets).

**【Contact for more information】**

Nobelpharma Co., Ltd.

Kozo Hayase, Executive Director, Head of Administrative Affairs & Corporate Planning

Tel: 03-5651-1160